Welcome to our dedicated page for Fennec Pharmaceuticals news (Ticker: FENC), a resource for investors and traders seeking the latest updates and insights on Fennec Pharmaceuticals stock.
Fennec Pharmaceuticals Inc. reports developments as a commercial-stage specialty pharmaceutical company focused on PEDMARK® (sodium thiosulfate injection), a therapy used to reduce the risk of cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors. The company also markets the product in Europe and the United Kingdom under the PEDMARQSI® name and has disclosed a licensing arrangement for commercialization in additional non-U.S. markets.
Recurring news themes include PEDMARK product sales and financial results, commercialization updates, scientific abstracts, investigator-sponsored and real-world studies in cancer patients receiving cisplatin-based chemotherapy, product exclusivity and patent matters, and equity compensation actions under Nasdaq rules.
Fennec Pharmaceuticals (NASDAQ: FENC) reported FY2025 net product sales of $44.6M (up 50% YoY) and Q4 2025 net product sales of $13.8M (up 75% YoY). Cash was $36.8M at year-end after oversubscribed $42M equity offerings and a $21.5M debt paydown, leaving $0 debt outstanding. The company reported a FY2025 net loss of $10.1M and continues to expand PEDMARK adoption, investigator-led studies, and real-world data generation.
Fennec Pharmaceuticals (NASDAQ: FENC) will release full year and fourth quarter 2025 financial results before U.S. markets open on March 24, 2026.
Management will host an 8:30 a.m. ET conference call and webcast the same day; a replay will be archived on the company website for 30 days.
Fennec Pharmaceuticals (NASDAQ:FENC) announced a settlement with Cipla resolving PEDMARK patent litigation. The lawsuit will be dismissed and Cipla agrees not to market a generic sodium thiosulfate product until September 1, 2033, subject to earlier entry under certain circumstances. PEDMARK is FDA‑approved to reduce cisplatin‑related ototoxicity in pediatric patients ≥1 month; pivotal Phase 3 data and safety rates are summarized in prescribing information.
Fennec Pharmaceuticals (NASDAQ:FENC) announced a clinical research collaboration with Tampa General Hospital Cancer Institute to evaluate real-world use of sodium thiosulfate injection (PEDMARK®) for reducing cisplatin-related ototoxicity in adolescent, young adult (AYA) and adult patients with non-metastatic solid tumors.
The study will analyze clinical and audiology monitoring data; PEDMARK is approved for pediatric patients aged one month and older and has a NCCN 2A recommendation for AYA patients.
Fennec Pharmaceuticals (NASDAQ:FENC) presented multi-institutional real-world data on PEDMARK® for adults with head & neck cancers at MHNCS, Feb 19–21, 2026. A retrospective review of 15 adults found PEDMARK® given ≥6 hours after cisplatin was safely integrated into care with no disruption to curative-intent cisplatin delivery.
Most high-risk patients showed no measurable hearing loss during or after treatment, PEDMARK® had only isolated, self-limited infusion events and no grade 3–4 toxicities, supporting further exploration in head & neck cancer populations.
Southpoint Capital Advisors LP announced that on Dec 24, 2025 it disposed of beneficial ownership of 1,000,000 common shares of Fennec Pharmaceuticals (TSX: FENC), representing approximately 2.93% of outstanding common shares on a fully diluted basis. The Common Shares were sold at USD $7.50 per share. After the disposition, Southpoint reports it now controls or directs 2.7 million common shares, representing about 8% of outstanding shares on a fully diluted basis. Southpoint said the shares were disposed for investment purposes and that it may change its ownership or control through market transactions, private agreements, treasury issuances, or exercise of warrants.
Fennec Pharmaceuticals (NASDAQ:FENC) announced that City of Hope will initiate an investigator‑sponsored Phase I study (NCT07218913) to evaluate PEDMARK® (sodium thiosulfate) for prevention of cisplatin‑induced ototoxicity in adult men with stage II‑III metastatic testicular germ cell tumors on Dec 9, 2025. The study tests adding PEDMARK to standard cisplatin chemotherapy to reduce permanent hearing loss. PEDMARK is approved for pediatric localized non‑metastatic solid tumors and has a NCCN 2A recommendation for adolescent and young adult patients. Multiple other investigator‑initiated studies are under review or contracting, with additional details to be shared as programs progress.
Fennec Pharmaceuticals (NASDAQ: FENC) reported positive topline results from the investigator‑initiated Phase 2/3 STS-J01 study of PEDMARK® in Japan to reduce cisplatin‑induced hearing loss in pediatric and AYA patients.
The primary cohort (n=27, ages 3–18) met its endpoint: hearing loss rates were 24% (ASHA) and 16% (Brock) with PEDMARK®, versus historically reported cisplatin‑only rates of 56% (ASHA) and 63% (Brock). Pharmacokinetics showed no reduction in cisplatin exposure and tumor response rate was approximately 95%. PEDMARK® was well tolerated; no adverse events were attributed to the drug. Fennec plans to pursue registration in Japan and explore partnering or licensing opportunities.
Fennec Pharmaceuticals (NASDAQ: FENC) will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 1:00 p.m. ET. The session will be available via live webcast and an archived replay will be posted after the event.
Investors can access the live webcast via the provided webcast link or from the Events page in the Investors section of the company website (www.fennecpharma.com).
Fennec Pharmaceuticals (NASDAQ:FENC) announced it has repurchased and redeemed all outstanding convertible notes held by Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP, leaving the company with no outstanding debt.
The repurchase used proceeds from the company’s underwritten public offering in the U.S. and concurrent private placement in Canada, which closed on November 17–18, 2025. The aggregate repurchase and redemption price was $21,729,455.30 (comprised of $19,476,655.48 principal, $305,134.27 accrued interest, and a $1,947,665.55 redemption fee). The Petrichor notes had carried interest at prime with a 3.5% floor plus a 4.5% margin and were set to mature on August 19, 2027.